Listing & Compliance Notices

InfuSystem Holdings, Inc received a nyse_american noncompliance notice notice regarding late filing (rules 1007).

“April 2, 2024 , InfuSystem Holdings, Inc. (the "Company") received notice from the NYSE Regulation (the "Notice") stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (the "Exchange") under the timely filing criteria included in Section 1007 of the NYSE American Company Guide (the "Company Guide") because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Delinquent Report"), which was due to be filed with the Securities and Exchange Commission (the "SEC") no later than April 1, 2024”

Eiger BioPharmaceuticals, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“April 2, 2024, the Company received written notice (the “ Delisting Notice ”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, as a result of the Bankruptcy Petitions and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. The Delisting Notice also advises the Company of its right to appeal Nasdaq’s determination pursuant to procedures set forth in Nasdaq Listing Rule 5800 Series. The Company does not intend to pursue an appeal.”

UPEXI, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“April 1, 2024, Upexi, Inc. (the “ Company ”) received a letter (the “ Nasdaq Bid Price Letter ”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company’s common stock (the “ Common Stock ”) had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Bid Price Requirement ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days”

Rent the Runway, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2)).

“March 27, 2024, Rent the Runway, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that the Company is no longer in compliance with the minimum Market Value of Listed Securities (“MVLS”) of $35,000,000 required for continued listing on The Nasdaq Capital Market as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Minimum MVLS Requirement”). The Notice has no effect at this time on the listing of the Company’s Class A common stock, par value $0.001 per share, which continues to trade on The Nasdaq Capital Market under”

Data Storage Corp received a nasdaq compliance regained notice regarding audit committee (rules 5605(c)(2)).

“April 2, 2024, Data Storage Corporation (the “Company”) received a letter (the “Notification Letter”) from The Nasdaq Stock Market (“Nasdaq”) stating that based on the information regarding the appointment of Nancy M. Stallone, CPA to the Company’s Board of Directors and Audit Committee, as detailed in the Company’s Current Report on Form 8-K, as filed on March 11, 2024 with the Securities and Exchange Commission, Nasdaq has determined that the Company complies with the Audit Committee requirement for continued listing on The Nasdaq Capital Market set forth in Listing Rules 5605(c)(2), which r”

Casa Systems Inc received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 27, 2024, Casa Systems, Inc. (the “Company”) received a letter (the “Letter”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s common stock would be delisted, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on the Nasdaq Global Select Market, as set forth in Nasdaq Listing Rules 5450(a)(1) (the “Bid Rule”). The Letter stated that the Company’s common stock would be scheduled for delisting at the opening of business on April 5, 2024, unless the Company timely requests a heari”

ACTELIS NETWORKS INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).

“March 27, 2024, the Company received a delist determination letter (the “Delist Letter”) from the Staff advising the Company that the Staff had determined to delist the Company’s securities from Nasdaq due to its non-compliance with the Equity Rule unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company has since timely requested a hearing, which request served to stay any further action by Nasdaq at least pending the hearing before the Panel and the expiration of any extension the Panel may grant following the hearing. At a hearing, the Company”

Nuvve Holding Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“March 27, 2024, Nuvve Holding Corp. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the bid price of the Company’s common stock has closed below the minimum $1.00 per share requirement for continued inclusion under Nasdaq Marketplace Rule 5550(a)(2) (the “Bid Price Rule”). The notice has no immediate effect on the listing or trading of the Company's common stock and the common stock will continue to trade on The Nasdaq Capital Market under the sym”

Microvast Holdings, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 26, 2024, Microvast Holdings, Inc. (the “Company”) received written notice from Nasdaq notifying it tha t the average closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1 per share during the last 30 consecutive trading days, as required for continued listing on the Nasdaq under Rule 5450(a)(1) of Nasdaq’s listing rules (the “Rules”). The notice has no immediate impact on the listing of the Company’s common stock and warrants, which will continue to be listed and trade on Nasdaq subject to the Company’s continued compliance with the othe”

Blue Star Foods Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 26, 2024, the Company received a letter from the Staff indicating that as of March 25, 2024, the Company has not regained compliance with the Minimum Bid Price Requirement for continued listing on Nasdaq. In order to be eligible for a second 180 day period, the Company must meet the initial listing requirements for Nasdaq. Nasdaq stated the Company is not in compliance with the $5,000,000 minimum stockholders’ equity initial listing requirement and, as such, is not eligible for a second 180 day period to regain compliance. The Company intends to appeal this determination and present its”

EverCommerce Inc. received a nasdaq noncompliance notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).

“March 29, 2024, the Company notified Nasdaq of its non-compliance with Nasdaq Rule 5605(c)(2)(A) as a result of the Vacancy and its intent to rely on the cure period provided to the Company by Nasdaq Rule 5605(c)(4)(B). The Company intends to appoint to the Audit Committee a third director who satisfies the criteria for service on the Audit Committee no later than 180 days after the effectiveness of Ms. Ellison-Taylor’s resignation.”

OneMedNet Corp received a nasdaq deficiency notice notice regarding minimum bid price (rules 5810(c)(3)(A)).

“pany’s security is at least $1 for a minimum of ten consecutive business days, Nasdaq will provide written confirmation of compliance and this matter will be closed. In the event the Company does not regain compliance with the Rule, the Company may be eligible for additional time under Listing Rule 5810(c)(3)(A)(ii). The Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency”

ARYA Sciences Acquisition Corp IV received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“March 26, 2024, ARYA received an additional and separate notice from the staff of the Listing Department of Nasdaq formally notifying ARYA that the deficiency under Nasdaq Listing Rule 5620(a) serves as an additional and separate basis for delisting and that the Panel will consider such additional matter at ARYA’s upcoming hearing (currently scheduled on April 25, 2024) to render a determination on ARYA’s continued listing on The Nasdaq Capital Market. There can be no assurance that ARYA will be able to satisfy Nasdaq’s continued listing requirements, obtain a favorable determination of the”

Newbury Street Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules IM-5101-2).

“March 26, 2024, Newbury Street Acquisition Corporation (the “Company”) received a notice (the “Nasdaq Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Listing Rule IM-5101-2 (the “Rule”), which requires that a special purpose acquisition company (“SPAC”) complete one or more business combinations within 36 months of the effectiveness of the registration statement filed in connection with its initial public offering. Since the Company’s registration statement became effective on March 22, 2021, it w”

Claritev Corp received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“March 28, 2024, MultiPlan Corporation (the “Company”) received a written notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) that it was not in compliance with the continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual (“Section 802.01C”), as the average closing price of the Company’s Class A common stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period ending March 27, 2024. The Notice has no immediate impact on the listing of the Company’s Common Stock on the NYSE, subject to the Company’s complia”

Momentus Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 27, 2024, Momentus Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Capital Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s Class A common stock, par value $0.00001 per share (the “Common Stock”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). The Notice has no immediate impact on th”

Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 27, 2024, Ensysce Biosciences Inc. (the “Company”) received a notice (the “Deficiency Letter”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. Nasdaq requires that Ensysce common stock have a minimum bid price of at least $1 per share (the “Minimum Bid Price”). In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 cal”

Chicken Soup for the Soul Entertainment, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 25, 2024, Chicken Soup for the Soul Entertainment Inc. (the “ Company ”) received a staff determination from The Nasdaq Stock Market (“ Nasdaq ”) to delist the Company’s securities from the Nasdaq Capital Market (the “ Staff Determination ”). As the Company previously reported in its Current Report on Form 8-K, filed with the SEC September 28, 2023, the Company received written notice from Nasdaq on September 23, 2023 (the “ September 2023 Notice ”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because for the prior 30 consecutive business days (th”

Alzamend Neuro, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“iled with the Securities and Exchange Commission (the “ SEC ”), which will remove the Common Stock from listing and registration on Nasdaq. The Company will request an appeal of the Staff’s determination to a Hearings Panel (the “ Panel ”), pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series, which is required to be submitted electronically no later than April 2, 2024. The hearing request will stay the suspension of the Common Stock and the filing of the Form 25-NSE pending the Panel’s decision, and the Common Stock will continue to trade on the Nasdaq Capital Market un”

ShiftPixy, Inc. received a nasdaq noncompliance notice notice regarding other (rules 5635(d)).

“March 28, 2024, ShiftPixy, Inc. (the “Company”) received a letter (the “Nasdaq Letter”) from the staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), which notifies the Company that the Staff has determined that the Company failed to comply with Nasdaq’s shareholder approval requirements set forth in Listing Rule 5635(d),1 which requires prior shareholder approval for transactions, other than public offerings, involving the issuance of 20% or more of the pre-transaction shares outstanding at less than the Minimum Price. As set forth in the let”

AVENUE THERAPEUTICS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A), 5550(b)(2)).

“March 26, 2024, the Staff issued a delist determination with respect to the deficiency, as required by the Nasdaq Listing Rules. Notwithstanding, and as previously disclosed, on February 15, 2024, the Company attended a hearing before the Nasdaq Hearings Panel (the “Panel”), at which the Company presented its plan to evidence compliance with both the minimum stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(2) (the “Equity Rule”) as well as the Bid Price Rule (together with the Bid Price Rule, the “Rules”). By decision dated March 11, 2024, the Panel granted the Company”

Gamida Cell Ltd. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“March 28, 2024, the Company received written notice (the “ Delisting Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Staff has, in accordance with Listing Rules 5101, 5110(b) and IM-5101-1, determined that the Company’s ordinary shares, par value NIS 0.01 per share (“ Ordinary Shares ”), will be delisted from Nasdaq based on the following factors: (i) the Restructuring Proceeding and the associated public interest concerns raised by such proceeding; (ii) concerns regarding the residual equity intere”

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding stockholders equity.

“March 26, 2024, the Company received written notice (the “Notice”) from the Staff stating that the Company is not eligible for a second 180 day compliance period for the Minimum Bid Price Rule deficiency because the Company does not comply with the $5,000,000 minimum stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The Notice indicates that the Company must present its views with respect to this deficiency to the Panel in writing no later than April 2, 2024, which it intends to do. Among other measures, the Company intends to schedule a special meeting of its sha”

INTRUSION INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 26, 2023, Intrusion Inc. (the “Company”) received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock (the “Common Shares”) over the 30 consecutive trading days from August 14, 2023, through September 25, 2023, had fallen below $1.00 per share, which is the minimum closing bid price required to maintain listing on Nasdaq under Listing Rule 5550(a)(2) (the “Minimum Bid Requirement”). Such notice additionally stated that in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company wou”

DIXIE GROUP INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“elisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing The Company announced today it received an extension of 180 calendar days from the NASDAQ Stock Market LLC (“Nasdaq”) to regain compliance with the Nasdaq’s minimum $1.00 bid price requirement set forth in Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market (the “bid price requirement”), following expiration of the initial 180 calendar day period to regain compliance with the Bid Price Requirement, and the Company’s written notice of its intent to cure the deficiency during the second compli”

Liberty Resources Acquisition Corp. received a nasdaq delisting notice notice regarding other (rules 5450(b)(2)(A), 5450(b)(2)(B), 5450(a)(2), 5620(a)).

“March 25, 2024, Liberty Resources Acquisition Corp. (the “ Company ”) received written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that in connection with the hearing on March 7, 2024 for previously disclosed on Form 8-K on December 8, 2023, Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq (the “ Decision ”) because of its failure to comply with Listing Rules 5450(b)(2)(A), 5450(b)(2)(B), 5450(a)(2), and Rule 5620(a). The Nasdaq notice also advises the Company of its right to request an ap”

Beneficient received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)(iii)).

“March 22, 2024, the Company received a letter from Nasdaq advising that the Nasdaq Staff (the “Staff”) had determined that, as of March 21, 2024, the Company’s Class A Common Stock had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As a result, the Staff determined to delist the Company’s securities from The Nasdaq Capital Market (the “Staff Determination”), unless the Company timely requests a hearing before the Nasdaq Hearin”

RiskOn International, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)(iii), 5550(a)(2)).

“March 22, 2024, RiskOn International, Inc., a Nevada corporation (the “ Company ”) received a letter (the “ Letter ”) from the Listing Qualifications staff (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Staff has determined the Company’s securities had a closing bid price of $0.10 or less for at least ten consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii). As previously disclosed, the Company has appealed a prior determination of the Staff to delist the Company’s c”

Bio Green Med Solution, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 27, 2024, Cyclacel Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications Staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1) because the Company reported stockholders’ equity of less than $2.5 million as of December 31, 2023. The Company’s stockholders’ equity was $607,000 as of December 31, 2023. The Company must submit a plan to the Staff no later than May 10, 2024 advising of actions it has taken or will take to regain compliance with Nasdaq Listing”

African Agriculture Holdings Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“March 21, 2024, African Agriculture Holdings Inc. (the “Company”) received written notice from Nasdaq notifying it that, for the 32 consecutive business days prior to the date of the Letter, the Company’s Market Value of Listed Securities (“MVLS”) was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A). The notice has no immediate impact on the listing of the Company’s common stock and warrants, which will continue to be listed and trade on Nasdaq subject to the Company’s continued compliance with the other l”

Galera Therapeutics, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C)).

“March 26, 2024, the Company received a letter from the Staff indicating that the Company has not regained compliance with the minimum Market Value of Publicly Held Shares (“MVPHS”) of $15,000,000 required for continued listing on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “Minimum MVPHS Requirement”), and that, unless the Company requests a hearing before a Panel to appeal Nasdaq’s delisting determination by 4:00 p.m. Eastern Time on April 2, 2024, trading of the Company’s common stock will be suspended at the opening of business on April 3, 2024, and the C”

PALISADE BIO, INC. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(b)(1)(A), 5605(c)(4)).

“March 22, 2024, the Company received a notice (the “Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with the audit committee requirements set forth in Nasdaq Listing Rule 5605. More specifically, as of the date of the Notice, the audit committee consists of only two (2) members, both of which are “independent directors,” as that term is defined in Nasdaq Listing Rule 5605(a)(2). Per Nasdaq Rules, the audit committee is required to be comprised of three (3) independent directors. The Notice states that”

GYRE THERAPEUTICS, INC. received a nasdaq compliance regained notice regarding audit committee (rules 5605).

“March 22, 2024, Gyre Therapeutics, Inc. (the “ Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it had regained compliance with the audit committee composition requirements as set forth in Nasdaq Listing Rule 5605 for continued listing on The Nasdaq Capital Market. As previously disclosed, on January 17, 2024, the Company was notified by Nasdaq that it was not in compliance with Nasdaq Listing Rule 5605 because its Audit Committee was not comprised of at least three “independent directors” (as defined in Nasdaq Listing Rule 5605(a)(2)). The C”

QUANTUM CORP /DE/ received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“March 19, 2024, Quantum Corporation (the “Company”) received a letter (the “Letter”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s common stock would be delisted, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rules 5450(a)(1) (the “Bid Rule”). The Letter stated that the Company’s common stock would be scheduled for delisting at the opening of business on March 28, 2024, unless the Company timely requests a hearing be”

QUANTUM CORP /DE/ received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 19, 2024, Quantum Corporation (the “Company”) received a letter (the “Letter”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company’s common stock would be delisted, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rules 5450(a)(1) (the “Bid Rule”). The Letter stated that the Company’s common stock would be scheduled for delisting at the opening of business on March 28, 2024, unless the Company timely requests a hearing be”

Fisker Inc./DE received a nyse delisting notice notice regarding minimum bid price (rules 802.01D).

“March 25, 2024, the New York Stock Exchange (the “NYSE”) notified Fisker Inc. (the “Company” or “Fisker”) that the NYSE had determined to (A) immediately suspend trading in the Company’s Class A common stock, par value $0.00001 per share (the “Class A Common Stock”), due to “abnormally low” trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual, and (B) commence proceedings to delist the Class A Common Stock. A delisting of our Class A Common Stock will trigger a requirement to offer to repurchase our unsecured 2.50% convertible notes due 2026 (the “2026 Notes”) and”

Venus Concept Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1), 5550(b)).

“March 20, 2024, the Company received a decision from the Panel granting its request for continued listing on the Nasdaq Capital Market, subject to the Company demonstrating compliance with Nasdaq Listing Rule 5550(b) on or before May 28, 2024, and certain other conditions.”

AGILE THERAPEUTICS INC received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“disclosed, on March 27, 2023, the Company received a letter from the Nasdaq Listing Qualifications Department (the “Staff”) indicating that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(b)(1) requiring companies listed on the Nasdaq Capital Market to maintain stockholder’s equity of at least $2,500,000 (the “Rule”). On June 2, 2023, based on the Staff’s review of the materials submitted by the Company, the Staff granted the Company’s request for an extension until September 25”

3D SYSTEMS CORP received a nyse deficiency notice notice regarding late filing (rules 802.01E).

“March 18, 2024, 3D Systems Corporation (the “Company”) received a notice (the “NYSE Notice”) from the New York Stock Exchange (the “NYSE”) that the Company is not in compliance with Section 802.01E of the NYSE Listed Company Manual as a result of its failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) with the Securities and Exchange Commission (the “SEC”). The NYSE Notice has no immediate effect on the listing of the Company’s common stock on the NYSE. The NYSE Notice informed the Company that, under NYSE rules, the Company has s”

ProSomnus, Inc. received a nasdaq delisting notice notice regarding late filing (rules 5450(b)(2)(C), 5810(c)(3)(C), 5450(a)(1)).

“September 21, 2023, on September 18, 2023, ProSomnus, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that it was no longer in compliance with the minimum Market Value of Publicly Held Shares (the “MVPHS”) of $15,000,000 required for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), Nasdaq afforded the Company an initial complian”

Rubicon Technologies, Inc. received a nyse deficiency notice notice regarding market value (rules 802.01B, 802.01C, 802.02).

“March 18, 2024, Rubicon Technologies, Inc. (the “ Company ”) received written notice (the “ Notice ”) from the New York Stock Exchange (the “ NYSE ”) that it was not in compliance with the continued listing standard set forth in Section 802.01B of the NYSE Listed Company Manual (the “ Minimum Market Capitalization Standard ”) because its average global market capitalization over a consecutive 30 trading-day period was less than $50.0 million and, at the same time, its last reported stockholders’ equity was less than $50.0 million. As set forth in the Notice, the Company also no longer satisfie”

African Agriculture Holdings Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“March 18, 2024, African Agriculture Holdings Inc. (the “Company”) received written notice from Nasdaq notifying it that the average closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1 per share during the last 30 consecutive trading days, as required for continued listing on the Nasdaq under Rule 5450(a)(1) of Nasdaq’s listing rules (the “Rules”). The notice has no immediate impact on the listing of the Company’s common stock and warrants, which will continue to be listed and trade on Nasdaq subject to the Company’s continued compliance with”

VEEA INC. received a nasdaq deficiency notice notice regarding other (rules IM-5101-2).

“March 18, 2024, Plum Acquisition Corp. I (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has failed to comply with Nasdaq Listing Rule IM-5101-2, which requires that a special purpose acquisition company must complete one or more business combinations within 36 months of the effectiveness of its IPO registration statement. Pursuant to the Notice, unless the Company timely requests a hearing before The Nasdaq Hearings Panel (the “Panel”), the Company’s securities will be sub”

Healthcare Triangle, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“March 20, 2024, Healthcare Triangle, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Stock Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. In its annual report on Form 10-K for the period ended December 31, 2023, the Company reported stockholders’ equity of $538,000, and, as a result, does not currently satisfy Listing Rule 5550(b)(1). Nasdaq’s letter has no immediate impact on the listing of the”

JOANN Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“March 20, 2024, JOANN, Inc. (the “Company”) was notified by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that Nasdaq had determined to delist the Company’s common stock, par value $0.01 per share (the “Common Stock”). Nasdaq reached its decision that the Company is no longer suitable for listing pursuant to Nasdaq Listing Rules 5101, 5110(b), and IM‐5101-1 as a result of the Company’s commencement of voluntary proceedings under Chapter 11 of the United States Bankruptcy Code (“Chapter 11”) on March 18, 2024. The Company does not intend to appeal this determin”

GridAI Technologies Corp. received a nasdaq deficiency notice notice regarding shareholders (rules 5635(d)).

“March 19, 2024, the Company received a Letter of Reprimand (the “Letter”) from the Staff in accordance with Nasdaq’s Listing Rule 5810(c)(4). The Staff’s determination relates to the offering and issuance by the Company (the “Offering”) of an aggregate of: (i) 610,000 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, (ii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 2,675,000 shares of Common Stock (the “Pre-Funded Warrant Shares”) and (iii) common warrants (the “Warrants”) to purchase up to an aggregat”

FOCUS UNIVERSAL INC. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(A), 5810(c)(3)(C)).

“March 22, 2024, Focus Universal Inc. (the “Company”), received two separate letters from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”). The March 20, 2024 letter was notifying the Company that based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets the Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). In addition, on March 22, 2024, Nasdaq notified the Company that since the Company’s Market Value of Listed Securities (“MVLS”) has fallen below $50,000,000 the Company no longer satisfies the require”

FOCUS UNIVERSAL INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(C)).

“March 20, 2024 and March 22, 2024, Focus Universal Inc. (the “Company”), received two separate letters from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”). The March 20, 2024 letter was notifying the Company that based upon the closing bid price for the last 30 consecutive business days, the Company no longer meets the Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”). In addition, on March 22, 2024, Nasdaq notified the Company that since the Company’s Market Value of Listed Securities (“MVLS”) has fallen below $50,000,000 the Company no longer sa”

Presurance Holdings, Inc. received a nasdaq compliance regained notice regarding market value (rules 5450(b)(1)(C)).

“March 19, 2024, the Company received approval from Nasdaq to transfer the listing of the Company’s Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market (the “Approval”). The Company’s Common Stock was transferred to the Nasdaq Capital Market effective as of the open of business on March 21, 2024, and continues to trade under the symbol “CNFR.” The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market, and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements. The Company’s 9.”

Cosmos Health Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“March 20, 2024, Cosmos Health Inc. (the “Company”) received a non-compliance letter from Nasdaq for its failure to maintain a minimum bid price of $1.00 per share for thirty (30) consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2). The Company has one hundred eighty (180) calendar days from March 20, 2024 to regain compliance by the closing bid price of the Company’s common stock being at least $1.00 per share for ten (10) consecutive business days. In the event the Company cannot otherwise regain compliance with the listing rule, it intends to effect a reverse stock sp”